MINNEAPOLIS, May 10, 2012 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to participate in the 2012 InvestMNt Conference being held at the Minneapolis Convention Center.
Phillip Nalbone, Vice President of Corporate Development, will present on Thursday, May 24th at 11:45am (CDT). To hear the live audio webcast of the panel discussion, go to the investor relations page of the Company's web site www.vasc.com and click on the "Investor Conferences" icon a few minutes prior to start time to download any necessary software.
About the CFA Society of Minnesota
Founded in 1952, the CFA Society of Minnesota is the greater Twin Cities Chapter of the CFA Institute, a global membership organization that awards the Chartered Financial Analyst (CFA) designation. The CFA Society of Minnesota is a vital part of the Minnesota investment community, with nearly 1,200 members from every segment of the finance industry who represent nearly 120 local financial institutions and upwards of $600 billion in assets under management. For additional information, connect to www.investmnt.org">www.investmnt.org.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of over 50 products and services in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products and services to interventional cardiologists, interventional radiologists, electrophysiologists and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2011 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.